References
- Alho, H., Sinclair, D., Vuori, E., & Holopainen, A. (2007). Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug & Alcohol Dependence, 88, 75–78
- Auriacombe, M., Fatseas, M., Dubernet, J., Daulouede, J. P., & Tignol, J. (2004). French field experience with buprenorphine. American Journal of Addiction, 13, S17–S28
- Bacha, J., Reast, S., & Pearlstone, A. (2010). Treatment practices and perceived challenges for European physicians treating opioid dependence. Heroin Addiction & Related Clinical Problems, 12, 9–19
- Bao, Y. P., Liu, Z. M., Epstein, D. H., Du, C., Shi, J., & Lu, L. (2009). A meta-analysis of retention in methadone maintenance by dose and dosing strategy. American Journal of Drug & Alcohol Abuse, 35, 28–33
- Bart, G. (2012). Maintenance medication for opiate addiction: The foundation of recovery. Journal of Addictive Diseases, 31, 207–225
- Bell, J. (2007). The role of supervision of dosing in opioid maintenance treatment. Available at: http://www.who.int/substance_abuse/activities/supervision_dosing.pdf [last accessed 2 Jan 2014]
- Benyamina, A., & Stöver, H. (2012). Barriers to treatment access and informed patient choice in the treatment of opioid dependence in Europe. Heroin Addiction & Related Clinical Problems, 14, 65–80
- Best, D., Rome, A., Hanning, K. A., White, W., Gossop, M., Taylor, A., & Perkins, A. (2010). Research for recovery: A review of the drugs evidence base. Scottish Government Social Research. Available at: http://www.scotland.gov.uk/Resource/Doc/321958/0103435.pdf [last accessed 2 Jan 2014]
- Caplehorn, J. R. (1994). A comparison of abstinence-oriented and indefinite methadone maintenance treatment. International Journal of Addiction, 29, 1361–1375
- Clausen, T., Anchersen, K., & Waal, H. (2008). Mortality prior to, during and after opioid maintenance treatment (OMT): A national prospective cross-registry study. Drug & Alcohol Dependence, 94, 151–157
- Connock, M., Juarez-Garcia, A., Jowett, S., Frew, E., Liu, Z., Taylor, R. J., Fry-Smith, A., Day, E., Lintzeris, N., Roberts, T., Burls, A., & Taylor, R. S. (2007). Methadone and buprenorphine for the management of opioid dependence: A systematic review and economic evaluation. Health Technology Assessment, 11, 1–171, iii–iv
- Dale-Perera, A., Goulão, J., & Stöver, H. (2012). Quality of care provided to patients receiving opioid maintenance treatment in Europe: Results from the EQUATOR. Heroin Addiction & Related Clinical Problems, 14, 23–38
- Degenhardt, L., Randall, D., Hall, W., Law, M., Butler, T., & Burns, L. (2009). Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: Risk factors and lives saved. Drug & Alcohol Dependence, 105, 9–15
- Department of Health, England. (2011). Public Health England's operating model factsheets. Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_131882 [last accessed 2 Jan 2014]
- Department of Health (England) and the Devolved Administrations. (2007). Drug misuse and dependence: UK guidelines on clinical management. London: Department of Health (England), the Scottish Government, Welsh Assembly Government and Northern Ireland Executive. Available at: http://www.nta.nhs.uk/uploads/clinical_guidelines_2007.pdf [last accessed 2 Jan 2014]
- Drummond, D. C., & Perryman, K. (2007). Psychosocial interventions in pharmacotherapy of opioid dependence: A literature review. Available at: http://www.who.int/substance_abuse/activities/psychosocial_interventions.pdf [last accessed 2 Jan 2014]
- Fareed, A., Vayalapalli, S., Casarella, J., & Drexler, K. (2012). Effect of buprenorphine dose on treatment outcome. Journal of Addictive Diseases, 31, 8–18
- Fischer, G., Nava, F., & Stöver, H. (2012). Outcomes of opioid-dependence treatment across Europe: Identifying opportunities for improvement. Heroin Addiction & Related Clinical Problems, 14, 39–50
- Fudala, P. J., Bridge, T. P., Herbert, S., Williford, W. O., Chiang, C. N., Jones, K., Collins, J., Raisch, D., Casadonte, P., Goldsmith, R. J., Ling, W., Malkerneker, U., McNicholas, L., Renner, J., Stine, S., & Tusel, D.; Buprenorphine/Naloxone Collaborative Study Group (2003). Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. New England Journal of Medicine, 349, 949–958
- Gerra, G., Saenz, E., Busse, A., Maremmani, I., Ciccocioppo, R., Zaimovic, A., Gerra, M. L., Amore, M., Manfredini, M., Donnini, C., & Somaini, L. (2011). Supervised daily consumption, contingent take-home incentive and non-contingent take-home in methadone maintenance. Progress in Neuropsychopharmacol & Biological Psychiatry, 35, 483–489
- Gordon, L., Tinsley, L., Godfrey, C., Parrott, S. (2006). The economic and social costs of Class A drug use in England and Wales, 2003/04; In: Home Office, Measuring different aspects of problem drug use: methodological developments. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/116642/hoor1606.pdf [last accessed 2 Jan 2014]
- Gossop, M., Marsden, J., Stewart, D., & Treacy, S. (2001). Outcomes after methadone maintenance and methadone reduction treatments: Two-year follow-up results from the National Treatment Outcome Research Study. Drug & Alcohol Dependence, 62, 255–264
- Goulão, J., & Stöver, H. (2012). The profile of patients, out-of-treatment users and treating physicians involved in opioid maintenance treatment in Europe. Heroin Addiction & Related Clinical Problems, 14, 7–22
- Gruber, V. A., Delucchi, K. L., Kielstein, A., & Batki, S. L. (2008). A randomized trial of 6-month methadone maintenance with standard or minimal counseling versus 21-day methadone detoxification. Drug & Alcohol Dependence, 94, 199–206
- Gunderson, E. W., Fiellin, D. A., Levin, F. R., Sullivan, L. E., & Kleber, H. D. (2006). Evaluation of a combined online and in person training in the use of buprenorphine. Substances Abuse, 27, 39–45
- HM Government. (2010). Drug strategy 2010: Reducing demand, restricting supply, building recovery: Supporting people to live a drug free life. Department of Health and Home Office. Available at: https://www.gov.uk/government/policies/reducing-drugs-misuse-and-dependence [last accessed 2 Jan 2014]
- Kamien, J. B., Branstetter, S. A., & Amass, L. (2008). Buprenorphine-naloxone versus methadone maintenance therapy: A randomised double-blind trial with opioid-dependent patients. Heroin Addiction & Related Clinical Problems, 10, 5–18
- Lind, B., Chen, S., Weatherburn, D., & Mattick, R. (2005). The effectiveness of methadone maintenance in controlling crime. British Journal of Criminology, 45, 201–211
- Maremmani, I., & Gerra, G. (2010). Buprenorphine-based regimens and methadone for the medical management of opioid dependence: Selecting the appropriate drug for treatment. American Journal of Addiction, 19, 557–568
- Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Systematic Reviews, 2009, CD002209
- Mattick, R. P., Kimber, J., Breen, C., & Davoli, M. (2008). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Systematic Reviews, 2008, CD002207
- National Institute for Health and Care Excellence. (2007). Guidance: Methadone and buprenorphine for the management of opioid dependence. Available at: http://www.nice.org.uk/nicemedia/pdf/TA114Niceguidance.pdf [last accessed 2 Jan 2014]
- National Treatment Agency for Substance Misuse. (2012). Medications in recovery: Re-orientating drug dependence treatment. National Health System. Available at: http://www.nta.nhs.uk/uploads/medications-in-recovery-main-report3.pdf [last accessed 2 Jan 2014]
- Orman, J. S., & Keating, G. M. (2009). Buprenorphine/naloxone: A review of its use in the treatment of opioid dependence. Drugs, 69, 577–607
- Paraherakis, A., Charney, D. A., Palacios-Boix, J., & Gill, K. (2000). An abstinence-oriented program for substance use disorders: Poorer outcome associated with opiate dependence. Canadian Journal of Psychiatry, 45, 927–931
- Scottish Government. (2008). The road to recovery: a new approach to tackling Scotland's drug problem. Available at: http://www.scotland.gov.uk/Publications/2008/05/22161610/0 [last accessed 2 Jan 2014]
- Simojoki, K., & Alho, H. (2013). A five-year follow-up of buprenorphine abuse potential. Journal of Alcoholism & Drug Dependence, 1, 1–6
- Sorensen, J. L., & Copeland, A. L. (2000). Drug abuse treatment as an HIV prevention strategy: A review. Drug & Alcohol Dependence, 59, 17–31
- Stöver, H. (2012). Assessing the current state of public-health-related outcomes in opioid dependence across Europe: Data from the EQUATOR analysis. Heroin Addiction & Related Clinical Problems, 14, 51–64
- Stöver, H. (2011). Barriers to opioid substitution treatment access, entry and retention: A survey of opioid users, patients in treatment, and treating and non-treating physicians. European Addiction Research, 17, 44–54
- Taylor, M., & Lewis, L. (2011). An economic analysis of the impact of crime and hospitalisation associated with different interventions for opioid abuse in the United Kingdom. Presented at the ISPOR 14th Annual European Congress. (Abstract PMH27)
- Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994). Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clinical Pharmacology & Therapeutics, 55, 569–580
- Welsh Assembly Government. (2008). Working together to reduce harm the substance misuse strategy for Wales 2008–2018. Available at: www.wales.gov.uk/topics/housingandcommunity/safety/publications/strategy0818/?lang=en [last accessed 2 Jan 2014]
- Winstock, A. R., Lea, T., & Sheridan, J. (2008). Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia. International Journal of Drug Policy, 19, 450–458
- World Health Organization. (2004). WHO/UNODC/UNAIDS position paper: Substitution maintenance therapy in the management of opioid dependence and HIV/AIDS prevention. Available at: www.who.int/substance_abuse/publications/treatment/en/index.html [last accessed 2 Jan 2014]
- World Health Organization. (2009). Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Available at: www.who.int/substance_abuse/publications/treatment/en/index.html [last accessed 2 Jan 2014]